Dawn of the Era of Treatable Alzheimer’s Disease
In this course, review opportunities that exist to improve our cognition regardless of if mild cognitive impairment (MCI) and subjective cognitive impairment (SCI), conditions - that can be precursors to Alzheimer’s disease - are present.
Dale Bredesen, MD
Board Review Series
AIHM 2018 Annual Conference
Time to Complete
What you will learn
The background and mechanisms driving Alzheimer’s disease and its precursors, SCI and MCI, will be described, along with an effective, personalized, programmatic approach to prevention and treatment. Specific patient results, subtypes, and new insights will be presented.By the end of this course, learners will be able to:
- Identify the subtypes of Alzheimer’s disease
- Evaluate patients with dementia or dementia risk
- Recognize how to treat patients with Alzheimer’s or pre-Alzheimer’s effectively
Certificate of Completion
Included in this course
Dale Bredesen, MD
Dale E. Bredesen, MD, is internationally recognized as an expert in the mechanisms of neurodegenerative diseases such as Alzheimer’s disease. He graduated from Caltech then earned his MD from Duke University Medical Center in Durham, North Carolina. He served as chief resident in neurology at the University of California, San Francisco (UCSF) before joining Nobel Laureate Stanley Prusiner’s laboratory at UCSF as a National Institutes of Health postdoctoral fellow. He has held faculty positions at UCSF; the University of California, Los Angeles; and the University of California, San Diego. Dr Bredesen directed the Program on Aging at the Burnham Institute before coming to the Buck Institute in 1998 as its founding president and CEO.
The CME for this course has expired, however you will continue to have access to your purchased content.
This course is self-paced with no set beginning or end date. You may complete this course on your own schedule and pace. Enrolling in and purchasing this course grants you access to its contents in perpetuity.